Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy
Autor: | Aleksandar Miljkovic, Desanka Grković, Sofija Davidović, Sandra Jovanović, Nikola Babić, Sava Barisic |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine medicine.medical_specialty Serum erythropoietin endocrine system diseases Angiogenesis Visual Acuity Gastroenterology 03 medical and health sciences 0302 clinical medicine lcsh:Ophthalmology Diabetic retinopathy Internal medicine Diabetes mellitus medicine Humans In patient Elisa method Stage (cooking) Erythropoietin Intraocular Pressure Aged Aged 80 and over Glycated Hemoglobin business.industry General Medicine Middle Aged medicine.disease eye diseases Ophthalmology Cross-Sectional Studies 030104 developmental biology Diabetes Mellitus Type 2 lcsh:RE1-994 Case-Control Studies 030221 ophthalmology & optometry Female Growth factors business Research Article medicine.drug |
Zdroj: | BMC Ophthalmology, Vol 19, Iss 1, Pp 1-8 (2019) BMC Ophthalmology |
ISSN: | 1471-2415 |
DOI: | 10.1186/s12886-019-1240-9 |
Popis: | Background Erythropoietin (EPO) is one of the systemic angiogenic factors, and its role in ocular angiogenesis and in diabetic retinopathy (DR) is not yet fully understood. The latest research data reveal a possible correlation of higher erythropoietin concentrations in the blood and in the eye with the development of more advanced stages of DR. The main aim of this work was to examine the possible influence of serum concentrations of erythropoietin on the development of diabetic retinopathy in patients with diabetes mellitus type 2. Methods The research involved 90 patients examined at the University Eye Clinic of the Clinical Center of Vojvodina, Novi Sad, Serbia. The first group comprised 60 patients with diabetes mellitus lasting for 10 years or more, with diabetic retinopathy. The second, control group consisted of 30 healthy individuals. In the first group of 60 patients with diabetes, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR). Laboratory EPO serum levels were determined, and they were correlated to the stage of DR. Concentration of EPO was assessed by ELISA method. Results The highest average concentration of EPO in serum (9.95 mIU/ml) was determined in the group of people with diabetes with PDR. The lowest average concentration of EPO in the serum (6.90 mIU/ml) was found in the control group. The average concentration of EPO in serum in the group of patients with diabetes with NPDR was 7.00 mIU/ml. The EPO concentration in serum was elevated in the group of PDR, and it was directly proportional to the level of the clinical stadium of PDR, being significantly higher in the moderate and severe subgroup of PDR comparing to the control healthy subjects, NPDR and mild PDR (p = 0.007). Conclusions Significantly elevated serum concentration of EPO in the advanced stages of DR, and positive correlation between EPO serum concentration and clinical stages of PDR, suggest that erythropoietin represents an important growth factor from blood, which plays a significant role in retinal ischemia and angiogenesis in diabetic retinopathy, especially in the proliferative stage of this disease. |
Databáze: | OpenAIRE |
Externí odkaz: |